Jacob Fischman received his BS in Biochemistry from Muhlenberg College where he focused on Immunology and host-pathogen interactions. During his undergraduate studies, Jacob performed independent research on host-pathogen interactions in the Giancarlo Cuadra Lab, which resulted in his 2020 first author publication on the impact of E-cigarette use on the oral microbiota. Throughout his undergraduate experience, Jacob demonstrated immense interest in therapeutics discovery and molecular mechanism, chronicled by his two consecutive internships at Regeneron Pharmaceuticals and his senior thesis on the molecular mechanism of Latent Tuberculosis infections. Jacob has continued to develop his interests in therapeutics through his work in the CAR T cell group at the van den Brink Lab.
Jacob currently resides within the CAR T cell research arm of the van den Brink lab, where he provides tech support on novel engineering projects to make CAR T cell therapy safer, stronger and more efficacious. His particular interests are in novel technologies development and transgene expression.
Following his time in the van den Brink Lab, Jacob intends to pursue PhD programs in immunology and/or bioengineering so that he may bolster his knowledge in order to better contribute to the future of cell and molecular therapy.